Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.74
(
-0.66%
)
Bitcoin
70,592.63
(
0.99%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 165793

Wednesday, 08/28/2013 10:18:14 PM

Wednesday, August 28, 2013 10:18:14 PM

Post# of 257262

Never heard of EPIRUS until today.

They were founded in 2011 and they keep a pretty low profile. Their business model is clearly directed toward FoB’s in emerging markets, so I don’t see them as major competition for the MNTA/BAX partnership.

According to the company’s fact sheet (http://www.epirusbiopharma.com/files/130711%20-%20EPIRUS%20Fact%20Sheet%20(Final).pdf ), Epirus has FoB’s in preclinical development for Humira, Avastin, Herceptin, and Rituxan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now